PMID- 31133438
OWN - NLM
STAT- MEDLINE
DCOM- 20200214
LR  - 20200214
IS  - 2352-3840 (Electronic)
IS  - 1499-2671 (Linking)
VI  - 43
IP  - 7
DP  - 2019 Oct
TI  - CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in 
      the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.
PG  - 464-471
LID - S1499-2671(18)30996-1 [pii]
LID - 10.1016/j.jcjd.2019.04.004 [doi]
AB  - OBJECTIVES: To describe patient-reported outcomes (PROs) after initiation of 
      treatment with canagliflozin (CANA) for type 2 diabetes mellitus (T2DM) in a 
      real-world Canadian setting. METHODS: CANadian CAnagliflozin REgistry (CanCARE) 
      is a prospective, observational, single-arm, real-world Canadian study of the 
      effectiveness and safety of CANA for the treatment of T2DM in 527 subjects. PRO 
      measures were collected in CanCARE using the Current Health Satisfaction 
      Questionnaire (CHES-Q) at baseline and after 3, 6 and 12 months of CANA treatment 
      to examine patient satisfaction regarding weight and overall health. Associations 
      between changes in satisfaction with weight, systolic blood pressure (SBP) and 
      glycated hemoglobin (A1C) levels were also investigated. RESULTS: Proportion of 
      patients satisfied with their body weight and overall health increased from 22.1% 
      and 26.9% at baseline to 32.4% and 49.2% after 12 months of CANA treatment, 
      respectively. Satisfaction rates also increased on CHES-Q domains representing 
      physical and emotional health. Correlations were found between improvement in 
      satisfaction with body weight and weight loss (r=-0.29; p<0.01) and between 
      improvements in satisfaction with overall health and weight loss (r=-0.13; 
      p=0.03) and SBP (r=-0.17; p<0.01), but not with changes in A1C level. 
      CONCLUSIONS: Treatment with CANA is associated with improvements in satisfaction 
      with body weight and overall health, which may be important drivers of patient 
      self-management and hold the potential to positively influence long-term outcomes 
      in T2DM.
CI  - Copyright (c) 2019 Canadian Diabetes Association. Published by Elsevier Inc. All 
      rights reserved.
FAU - Woo, Vincent
AU  - Woo V
AD  - University of Manitoba, Winnipeg, Manitoba, Canada. Electronic address: 
      Vwoo3@shaw.ca.
FAU - Bell, Alan
AU  - Bell A
AD  - University of Toronto, Toronto, Ontario, Canada.
FAU - Clement, Maureen
AU  - Clement M
AD  - University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Noronha, Luis
AU  - Noronha L
AD  - Diabetes Heart Research Center, Toronto, Ontario, Canada.
FAU - Tsoukas, Michael A
AU  - Tsoukas MA
AD  - McGill University Health Centre, Montreal, Quebec, Canada.
FAU - Camacho, Fernando
AU  - Camacho F
AD  - University of Waterloo, Waterloo, Ontario, Canada.
FAU - Traina, Shana
AU  - Traina S
AD  - Janssen Global Services, LLC, Raritan, New Jersey, United States.
FAU - Georgijev, Natasha
AU  - Georgijev N
AD  - Janssen Inc, Toronto, Ontario, Canada.
FAU - Rose, Jennifer B
AU  - Rose JB
AD  - Janssen Inc, Toronto, Ontario, Canada.
FAU - Sorabji, Delna
AU  - Sorabji D
AD  - Janssen Inc, Toronto, Ontario, Canada.
FAU - Bajaj, Harpreet S
AU  - Bajaj HS
AD  - LMC Diabetes & Endocrinology, Brampton, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20190416
PL  - Canada
TA  - Can J Diabetes
JT  - Canadian journal of diabetes
JID - 101148810
RN  - 0 (Blood Glucose)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
SB  - IM
MH  - Blood Glucose/analysis
MH  - Body Weight
MH  - Canada
MH  - Canagliflozin/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Reported Outcome Measures
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Prognosis
MH  - Prospective Studies
MH  - Registries/*statistics & numerical data
MH  - Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
MH  - Surveys and Questionnaires
MH  - Weight Loss
OTO - NOTNLM
OT  - canagliflozin
OT  - canagliflozine
OT  - diabete de type 2
OT  - health satisfaction
OT  - patient-reported outcomes
OT  - resultats rapportes par les patients
OT  - satisfaction a l'egard de la sante
OT  - satisfaction a l'egard du poids
OT  - type 2 diabetes
OT  - weight satisfaction
EDAT- 2019/05/28 06:00
MHDA- 2020/02/15 06:00
CRDT- 2019/05/29 06:00
PHST- 2018/12/07 00:00 [received]
PHST- 2019/02/20 00:00 [revised]
PHST- 2019/04/12 00:00 [accepted]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2020/02/15 06:00 [medline]
PHST- 2019/05/29 06:00 [entrez]
AID - S1499-2671(18)30996-1 [pii]
AID - 10.1016/j.jcjd.2019.04.004 [doi]
PST - ppublish
SO  - Can J Diabetes. 2019 Oct;43(7):464-471. doi: 10.1016/j.jcjd.2019.04.004. Epub 
      2019 Apr 16.